Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range374.00 - 3,900.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪23.05M
Enterprise Value7.56B
Total Cash (Recent Filing)₪8.54M
Total Debt (Recent Filing)₪71.00K
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Aug 27, 2026EPS Estimate
-49.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetVery low leverage reduces near-term financial risk and provides flexibility to fund clinical programs without high interest burden. This balance-sheet strength extends operational runway versus highly leveraged peers, supports partner negotiations, and lowers bankruptcy probability while trials progress.
Phase 3 Enrollment Completed (Piclidenoson)Completing enrollment and reaching an interim analysis under FDA/EMA-agreed protocol materially reduces development timing uncertainty. A defined Q4 2026/Q1 2027 readout window enables strategic planning, potential partner interest, and milestone-based financing options, de-risking a key program.
Namodenoson Phase 2a Showed Safety And Survival SignalsNamodenoson's positive Phase 2a safety and durable survival signals in advanced pancreatic patients provide clinical proof‑of‑concept and justify advancing to a Phase 2b combination study. Robust safety supports combo strategies, broadens development pathways, and increases attractiveness for collaboration.
Bears Say
Shrinking Revenue & Worsening LossesRevenue has declined materially while operating and net losses have widened, indicating the company cannot cover costs from product sales. Persistent losses depress returns on equity and signal continued reliance on external funding, increasing dilution risk and constraining long‑term financial sustainability.
Consistent Negative Cash GenerationOperating and free cash flow remain materially negative despite some improvement in 2025, meaning the company consumes cash annually to fund trials. Persistent cash burn necessitates further financing or partnerships to complete pivotal studies, limiting autonomy and increasing execution risk over the medium term.
No Approved Commercial ProductsAs a clinical‑stage biotech with no approved products, Can‑Fite's revenue profile is binary and depends on trial outcomes and regulatory approvals. This elevates commercial and regulatory risk, delays durable revenue generation, and requires development and commercialization partnerships to scale post-approval.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 374.00 and its highest was 3900.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪23.05M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 48 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -900.083 earnings per share for the quarter, missing the consensus estimate of -21.107 by -878.976.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -49.75.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -900.083 in its last earnings report, missing expectations of -21.107. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.